Varex Q2 FY26 slides: EPS beats amid 240bp margin compression

Varex Imaging beat Q2 fiscal 2026 expectations with revenue of $216 million versus $214.57 million consensus and non-GAAP EPS of $0.21 versus $0.20, but profitability weakened materially. Gross margin fell 240 bps to 34%, adjusted EBITDA dropped 25% to $27 million, and the stock slipped 2.79% after hours to $11.99. Management guided Q3 revenue to $210 million-$225 million and full-year revenue to $860 million-$880 million, while highlighting AI and photon-counting investments despite ongoing margin pressure.

Analysis

The market is signaling that this is less an earnings miss story than a quality-of-earnings and balance-sheet story. When revenue is flat but margins compress and cash flow turns negative, the equity stops trading on near-term beat/miss and starts trading on whether management can avoid a slow-motion de-rating; that usually takes multiple quarters to repair, not one. The inventory build is especially important: it ties up cash now, but it also implies either demand is being pulled forward into a fragile end market or procurement has become less disciplined, both of which can force more working-capital drag if end-market conversion stalls.

The second-order winner is likely the company’s larger, better-capitalized OEM and imaging peers that can price aggressively while VREX is still absorbing input-cost inflation and debt-service friction. AI and photon-counting investment is strategically necessary, but in the next 2-3 quarters it behaves more like an option on future mix improvement than an earnings lever; until those programs show meaningful attach rates, they can widen the gap between headline growth and cash generation. The more interesting risk is that industrial scans and cargo-system commissioning create lumpy revenue recognition, which can keep reported growth respectable while masking deteriorating underlying cash economics.

The market may be underestimating how sensitive the equity is to any further EBITDA downtick: with leverage already rising on a net basis, even modest execution slippage can compress the multiple faster than analysts cut numbers. Conversely, the setup can reverse quickly if gross margin stabilizes in the low-30s and working capital normalizes, because the stock is still far from distressed and liquidity is not yet the binding constraint. That makes this a classic “show-me” name: the next two quarters matter far more than the full-year guide, which appears to leave little room for execution error.

The contrarian view is that the selloff could be overdone if margin pressure is genuinely transitory and tied to a narrow set of inputs rather than structural pricing weakness. If management is right that new product pipelines are converting into OEM wins, the market is likely discounting that upside too slowly; however, the burden of proof is high because the current numbers look like a business funding future growth by consuming present free cash flow.

Key Decisions for Investors

• Short VREX on rallies over the next 2-6 weeks; thesis is that the stock will re-rate on cash burn and margin compression before any AI/photon-counting upside is visible. Risk/reward favors a tactical short because guidance leaves limited cushion if gross margin slips below 33%.
• Pair trade: long ILMN or HOLX vs short VREX for 1-2 quarters. The relative-value expression captures the market rewarding higher-margin, more durable cash generation while penalizing companies with inventory drag and leverage creep.
• Buy VREX downside protection via 3-6 month puts if borrow is expensive or short interest is crowded. Target strikes near the recent trading range to monetize a further de-rating if Q3 shows no gross margin recovery; max loss is known premium, upside is a sharper-than-expected liquidity scare.
• Avoid initiating fresh longs until there is evidence of sequential inventory drawdown and operating cash flow turning positive. If those two variables improve by the next print, reassess for a mean-reversion long; without them, the equity is a value trap candidate.
• For higher-risk traders, structure a call spread only as a catalyst trade into evidence of improved photon-counting orders or tariff-refund commentary. Keep size small: upside exists, but it is a 6-12 month story, while the downside can express immediately through another margin miss.